Lead investor is Virginia Life Science Investments

Rehovot, Israel and Richmond, VA – April 15, 2013 – ImmunArray, developer of a groundbreaking in-vitro diagnostic platform system, the iChip™, is pleased to announce the completion of a financing round of $5.2 Million, to support its ongoing development of additional products and plan for market entry in 2013. The round was led by Richmond-based, Virginia Life Science Investments, LLC.  The investment round included funds from existing investors and Alfred Tauber MD of the Lazlow Tauber Foundation. The company will also present preliminary data on their product (s) being developed to support the diagnosis, monitoring and rule out of Systemic Lupus Erythematosus (SLE) at the American Association of Immunology (AAI) and the International Congress of Immunology (ICI)  These data were developed in conjunction with academic centers in both the US and Israel. Transplant continues to be a market the company is evaluating in conjunction with a major pharmaceutical company with products in this market.  All products will be supported and available through Veracis™, the company’s service laboratory located on the campus of the Johns Hopkins Bayview Medical Center in Baltimore Maryland.”

Will support additional development and collaborations with Johns Hopkins University School of Medicine researchers

Richmond, VA and Rehovot, Israel - January 23, 2013 – ImmunArray, developer of the iCHIP™, a groundbreaking in-vitro auto-antibody detection technology, is pleased to announce the license and onset of development of potential tests to detect Acute Brain Injury in their development laboratory at Johns Hopkins Bayview Medical Center.

This represents the next step in the expansion of activity via their VERACIS™ subsidiary as the company furthers the development of clinical products licensed by Johns Hopkins University School of Medicine investigators Jennifer Van Eyk, Ph.D., and Allen Everett, M.D. The license provides access to novel biomarkers, which can pave the way to the development of a suite of tests for acute brain injury. The VERACIS Laboratory, a wholly owned subsidiary of ImmunArray USA, will provide testing services under CLIA and will also provide support to pharmaceutical projects and product development. The proteomics expertise and licensing capability resident in this relationship will allow for the development of further complimentary diagnostic products, with proprietary new antigens.

Will support development and collaborations with Johns Hopkins University School of Medicine Researchers

Richmond, VA and  Rehovot,  Israel - January 3, 2013 – ImmunArray, developer of the iCHIP™, a groundbreaking in-vitro auto-antibody detection technology, is pleased to announce the establishment of a service and development laboratory at the Johns Hopkins University School of Medicine and Johns Hopkins Bayview Medical Center.

VERACIS™ will collaborate with and intends to further the development of clinical products licensed by Johns Hopkins University School of Medicine investigators Jennifer Van Eyk, Ph.D., and Allen Everett, M.D. The establishment of this facility allows the company to provide analytical and diagnostic testing services to external collaborators and the company plans to establish quality systems and certification to provide testing services under CLIA. The VERACIS Laboratory will also provide support to pharmaceutical projects and product development as ImmunArray expands its activities in the US with pharmaceutical company relationships.

Richmond, Virginia and Rehovot, Israel

Brussels, June 18, 2012 - On March 1^st 2012 the IMI-JU funded project – Biomarkers for Enhanced Vaccine Safety (BioVacSafe) – initiated its collaborative work to develop new tools that will improve the evaluation and monitoring of vaccine immunosafety. BioVacSafe is a public private consortium of 19 partners involving three of Europe’s leading vaccine producing companies, experts from major academic institutions, small and medium-sized enterprises (SMEs) and non-governmental organization (NGO) actors.

Presents Data at American Transplant Congress (ATC) in June

Lead investor is Virginia Life Science Investment

Rehovot, Israel and Richmond, VA – April 13, 2012 – ImmunArray, developer of a groundbreaking in-vitro diagnostic platform system, the iChip™, is pleased to announce the completion of the first close of over $3M of an up to $5M funding goal to support product launch in 2013. The round is being led by Richmond-based, Virginia Life Science Investments, LLC. The investment round included funds from existing investor, the Lazlow Tauber Foundation. The company will also present preliminary data at the American Transplant Congress regarding detection of allograft rejection, initially in kidney transplant. These data were developed in conjunction with academic centers with major transplant programs.

Virginia Life Sciences Investments and others add further investments in the company

Rehovot, Israel and Richmond, VA - November 15, 2011 – ImmunArray, developer of the iChip, a groundbreaking in-vitro auto antibody detection technology, is pleased to announce the promotion of D. Scott Batty Jr., MD to Chief Executive Officer. Dr. Batty will focus on optimizing the development of both commercial opportunities for entry into diagnostic markets as well as fully-developing the capabilities of the pharmaceutical development platform.

Lead investor is Virginia Life Science Investments

Rehovot, Israel and Richmond, VA - September 6, 2011 – ImmunArray, developer of the iChip, a groundbreaking in-vitro auto antibody detection technology, is pleased to announce the addition of D. Scott Batty Jr., MD to the executive management team. Dr. Batty will assume the position of EVP and his initial focus will be to direct and accelerate the company’s expanding experience and capabilities in support of selected Pharmaceutical Company Alliances.

Lead investor is Virginia Life Science Investments

Rehovot, Israel and Richmond, VA – May 3, 2010 – ImmunArray, developer of a groundbreaking in-vitro diagnostic platform system, the iCHIP,is pleased to announce the completion of a $1.2 million financing round, led by Richmond-based, Virginia Life Science Investments, LLC. The investment round also included funds from existing investors and constitutes a significant milestone for ImmunArray as it enters into its next phase of development.

April 2009 - Formulated the strategy for product launch in the US

April 2009 - Agreement with Brigham & Womens Hospital (Boston, MA) to provide early lung cancer specimens.

Rehovot, ISRAEL, and Rockville, MARYLAND - December 22, 2008 -- ImmunArray Ltd., (Rehovot, Israel) and 20/20 GeneSystems Inc. (Rockville, MD) announce that their two companies have been awarded a grant of $950,000 from the US-Israel Binational Industrial R&D Foundation (BIRD-F). The shared grant will be used to jointly develop a blood test for early diagnosis of lung cancer.

July 2008-Cardiovascular validation study: blinded validation test of heart attack samples completed successfully (with Erasmus Medical Center Rotterdam, Netherlands).

February 2008 – IAL graduates from the RadBiomed Incubator; Moved to own facilities at the Rabin Science Park, adjacent to the Weizmann Institute of Science in Rehovot, Israel.

January 2008 – Partnered with Virginia Biosciences Commercialization Center (Richmond, Virginia) to perform Business Development in N. America. Donna Edmonds named Director, BD, N. America.